Pharmacotherapy for pulmonary arterial hypertension

Review describes the clinical implications of a provisionally reported study (n=247) which found no significant difference in change in pulmonary vascular resistance for selexipag vs placebo after 14 days of macitentan plus tadalafil.

The Lancet Respiratory Medicine